Synergiczne działanie amoksycyliny i witaminy C na Helicobacter pylori in vitro

• Autorzy: Popowski J , Jarosz M.
• Języki publikacji: PL

Abstrakty

PL

Ustalono maksymalne stężenia kwasu askrobinowego (witaminy C) oraz amoksycyliny pozwalające na wzrost na podłożach bakteriologicznych ponad 90% klinicznych szczepów Helicobacter pylori, pod warunkiem, że każda z tych substancji będzie zastosowana oddzielnie. Przy jednoczesnym wprowadzeniu do podłoża kwasu askrobinowego i amoksycylliny w uprzednio stosowanych stężeniach obserwuje się silny efekt synergicznego działania, prowadzący do zahamowania wzrostu większości badanych szczepów. Rozważana jest możliwość zastosowania powyższej kombinacji w terapii.

EN

Maximal concentrations of ascorbic acid (vitamin C) and amoxicillin alowing for growth of about 90% of clinical Helicobacter pylori strains in bacteriological media was determined, when each of these substance was tested separately. Strong synergistic effect was observed when both subsances were used together in the concentrations previously determined. This effect resulted in the growth inhibition of the majority of tested H. pylori strains. Possible application of these compounds in therapy of H. pylori infections is cosidered.

Słowa kluczowe

PL

kwas askorbinowy; podloza hodowlane; synergizm; amoksycylina; bakterie; hodowla in vitro; Helicobacter pylori

• Wydawca: -
• Czasopismo: Żywienie Człowieka i Metabolizm
• Rocznik: 1999
• Tom: 26
• Numer: 1
• Opis fizyczny: s.34-38,tab.,bibliogr.

Twórcy

autor

Popowski J

• Instytut Zywnosci i Zywienia, 02-903 Warszawa, ul.Powsinska 61-63

autor

Jarosz M.

Bibliografia

• 1. Axon A.T.R.: H. pylori therapy: Effect on peptic ulcer disease. J. Gastroenterol. Hepatol., 1991, 6, 131.
• 2. Barbara L., Biasco G., Capurso L.: Effects of surcralfate and sulglycotide on active gastritis and H. pylori colonization. Am. J. Gastroenterol., 1990, 85, 1.
• 3. Cliodna A., McNulty M., Geatry J.C.: C. pyloridis and associated gastritis: investigator blind placebo controlled trial of bismuth salicylate and erythromycin. Brit. Med. J., 1986, 293, 645.
• 4. Coghlan J.G., Gilligan D., Humphries H.: C pylori and recurrence of duoderal ulcers. Lancet 1987, 2, 1109.
• 5. Forne M., Viver J.M., Espinos J.C.: Colloidal bismuth subcitrate is necessary in one week therapy with omeprazole and clarithromycin in the treatment of H. pylori associated duodenal ulcer. Gastroenterology 1994, 106, A77.
• 6. Glupczyński Y., Delmee M., Bruck M.: Susceptibility of clinical isolates of C. pylori to 24 antimicrobiol. and anti-ulcer agents. Eur. J. Epidemiol., 1988, 4, 154.
• 7. Goldie J., Jalali S., Van Zanten S., et al.: Ascorbic acid inhibits the growth and urease activity of Campylobacter pylori. Gut 1989, 30, A1484.
• 8. Goodwin C.S., Blake P., Blincow E.: The minimum inhibitory bactericidal concentrations of antibiotics and anti-ulcer agents against C. pyloridis. J. Antimicr. Chemoth., 1986, 17, 309.
• 9. Gustavson L.E., Kaiser J.F., Mukherjee D.X.: Evaluation of pharmacokinetics drug interactions between clarithromycin and omeprazole. Am. J. Gastroenterol., 1994, 89, 1373.
• 10. Hisking S.W., Lin T.K.W., Chung S.C.S.: Duodenal ulcer healing by eradication of H. pylori without anti-acid treatment: randomise controlled trial. Lancet 1994, 343, 508.
• 11. Iwahi T.: Lansoprazole, a novel benzimidazole proton pomp inhibitor have selective activity against H. pylori. Antimicrob. Agents Chemother., 1991, 35, 127.
• 12. Jarosz M., Dzieniszewski J., Dąbrowska-Ufniarz E., et al.: Effects of high vitamine C doses on Helicobacter pylori infection and vitamine C concentration in gastric juice. Gut 1997, 41 (suppl. 3), 165.
• 13. Kasper G., Dickgiesser N.: Antibiotic sensitivity of clinical isolates of C. pyloridis to 11 antimicrobial agents. Eur. J. Clin. Microbiol., 1984, 3, 444.
• 14. Lambert T., Megraud F., Gerbaud G.: Susceptibility of C. pyloridis to 20 antimicrobial agents. Antimicrob. Agents Chemother., 1986, 30, 510.
• 15. Logan R.P.H., Bardhan K.D., Celestin L.R.: Healing of DU and eradication of H. pylori by clarithromycin and omeprazole. Gastroenterology 1994, 106, A126.
• 16. Logan R.P.H., Gummett P.A., Schaufelberger D.H.: Eradication of H. pylori witg clarithromycin and omeprazole. Gut 1994, 35, 323.
• 17. Logan R.P.H.: Helicobacter pylori and gastric cancer. Lancet 1994, 344, 1078.
• 18. McNulty C.A.M., Dent J.C., Wise R.: Susceptibility of clinical isolates of C. pyloridis to 11 antimicrobial agents. Antimicrob. Agents Chemother., 1985, 28, 837.
• 19. Nilius M., Bode G., Lehnhardt G., et al.: In vitro inhibition of Helicobacter pylori urease: biochemical andultrastructural analysis. Eur. J. Clin Invest., 1991, 21, 551.
• 20. Noach L.A., Langenberg W.L., Bertola M.A.: Impact of metronidazole resistance on the eradication of H. pylori. Scand. J. Infect. Dis., 1994, 26, 321.
• 21. O’Morain C., Dettmer A., Rambow A.: Dual therapy with clarithromycin and omeprazole for the treatment of active duodenal ulcers. Am. J. Gastroenterol., 1994, 89, 1384.
• 22. Penston J.G.: Helicobacter pylori eradication: understandable coution but no excuse for inertia. Aliment. Pharmacol. Ther., 1994, 8, 369.
• 23. Rauws E.A.J., Tytgat G.N.J.: Cure of duodenal ulcer associated with eradication of H. pylori. Lancet 1990, 335, 1233.
• 24. Sung J.Y., Chung S.C.S., Ling T.K.W.: Antibacterial treatment of gastric ulcers associated with H. pylori N. Engl. J. Med., 1995, 332, 139.
• 25. Tatsuta M., Ishikawa H., Jishi H.: Reducation of gastritis ulcer recurrence after suppression of H. pylori by cefaxime. Gut 1990, 31, 349.
• 26. The Helicobacter pylori Study Group: The Maastricht Consensus Report: Current European concepts in the menagement of Helicobacter pylori infection. Gut 1997, 41, 8.
• 27. Tytgat G.N.J.: Treatments that impact favourably upon the eradication of H. pylori and ulcer recurrence. Aliment. Pharmacol. Ther., 1994, 8, 359.
• 28. Vogt K., Warrelman M., Hahn H.: Effect of bismuth subcarbonate against C. pylori. Zblt. Bakt., 1990, 273, 370.
• 29. Westblom T.U., Guldipati S., Midkiff B.R.: In vitro susceptibility of H. pylori to the new oral cephalosporins cefpodoxime and cefixime. Europ. J. Clin. Microbiol. Inf. Dis., 1990, 9, 277.
• 30. Xiao S.D., Liu W.Z., Xia D.H.: The efficacy of furazolidone and metronidazole in the treatment of chronic gastritis associated with H. pylori. Hepato-Gastroenterol., 1990, 37, 297.